Posology : מינונים

4.2    Posology and method of administration

Posology
Children (from 2 years of age), adolescents and adults

Menveo should be administered as a single dose (0.5ml).


Menveo_DR V4.0_notification_13.06.2019_clean                            Page 1 of 16 To ensure optimal antibody levels against all vaccine serogroup, the primary vaccination schedule with Menveo should be completed one month prior to risk of exposure to Neisseria meningitidis group A, C, W- 135 and Y. Bactericidal antibodies (hSBA≥1:8) were observed in at least 64% of subjects at 1 week post vaccination (see section 5.1 for immunogenicity data per individual serogroups).

Older people

There are limited data in individuals aged 56-65 and there are no data in individuals aged >65 years.
Booster vaccination

The effect of booster dose and Long-term antibody persistence data following vaccination with Menveo are available up to 5 years after vaccination of children and adolescents aged 2-18 years (see section 4.4 and 5.1).

Menveo may be given as a booster dose in subjects who have previously received primary vaccination with Menveo, other conjugated meningococcal vaccine or meningococcal unconjugated polysaccharide vaccine.
The need for and timing of a booster dose in subjects previously vaccinated with Menveo is to be defined based on national recommendations.

Paediatric population (under 2 years of age)

The safety and efficacy of Menveo in children under 2 years of age has not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.

Method of administration

Menveo is given as an intramuscular injection, preferably into the deltoid muscle.
It must not be administered intravascularly, subcutaneously or intradermally.
Separate injection sites must be used if more than one vaccine is being administered at the same time.

For instructions on preparation and reconstitution of the medicinal product before administration, see section 6.6.